KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis

@inproceedings{Lohinai2017KRASmutationIA,
  title={KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis},
  author={Zoltan Lohinai and Thomas Klikovits and Judit Moldvay and Gyula Ostoros and Erzsebet Raso and J{\'o}zsef T{\'i}m{\'a}r and Katalin Fabian and Ilona Kovalszky and Istv{\'a}n Kenessey and Clemens Aigner and Ferenc R{\'e}nyi-V{\'a}mos and Walter Klepetko and Balazs Dome and Bal{\'a}zs Hegedűs},
  booktitle={Scientific reports},
  year={2017}
}
Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC). We investigated the effect of KRAS mutation on overall survival (OS) in this setting. In our retrospective study, 500 consecutive Caucasian metastatic LADC patients with known KRAS mutational status were analyzed after… CONTINUE READING